Cost minimisation of RSV prevention with palivizumab
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Decreasing cost of treatment by promoting sharing of vials

    Dear Editor,

    Dr. Wills and colleagues have reported their experience in cost minimization by promoting sharing of vials of palivizumab for prophylaxis against respiratory syncytial virus infection. Our experience suggests that this idea can be extended to several other fields of medicine.

    The use of intravenous and oral contrast agents is a matter of routine practice. Many a times, especially in pediatric...

    Show More
    Conflict of Interest:
    None declared.